Back to all papers

Performance of MRI-based deep learning models in differentiation of triple negative breast cancer from other breast cancer subtypes: A systematic review and meta-analysis.

August 24, 2026pubmed logopapers

Authors

Mohammadzadeh S,Kiani I,Rahmani SAMS,Mirzai M,Elhaie M,Dahaj ME,Rahimi M,Mosadegh M,Mohammadzadeh S,Gity M

Affiliations (5)

  • Advanced Diagnostic and Interventional Radiology Research Center (ADIR), Tehran University of Medical Sciences, Imam Khomeini Hospital, Tehran, Iran.
  • School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Iranian Center of Neurological Research, Neuroscience Institute, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Medical Physics, School of Medicine Isfahan University of Medical Sciences, Iran.
  • School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.

Abstract

Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited targeted therapies. Deep learning (DL) applied to magnetic resonance imaging (MRI) offers a promising noninvasive alternative to biopsy. This systematic review and meta‑analysis aimed to synthesize current evidence on the diagnostic performance of MRI‑based DL models for identifying TNBC. Comprehensive searches of PubMed, Scopus, and Web of Science were conducted up to December 5, 2025. Eligible studies evaluated histologically confirmed breast cancer using MRI and DL‑based models for distinguishing TNBC from non‑TNBC. Study quality was assessed using the METRICS. Pooled diagnostic estimates were computed using a bivariate random-effects model in Stata version 18. Sensitivity analyses and publication bias tests were performed. Certainty of evidence was evaluated by GRADE. Nine studies comprising 2985 patients met inclusion criteria. Pooled estimates in the validation cohorts demonstrated an AUC of 0.85 (95% CI: 0.81-0.88), sensitivity of 0.83 (95% CI: 0.76-0.89), specificity of 0.87 (95% CI: 0.82-0.91), positive likelihood ratio of 6.47 (95% CI: 3.98-10.54), negative likelihood ratio of 0.24 (95% CI: 0.18-0.33), and diagnostic odds ratio of 26.53 (95% CI: 13.86-50.81). Heterogeneity was moderate (I²=30.2%), and no publication bias was detected. Sensitivity analysis revealed no influential individual study. Evidence certainty was rated as low. DL models applied to breast MRI showed potential for noninvasive TNBC identification with high diagnostic accuracy. However, limited external validation and variability in methodological quality highlight the need for standardized, multicenter studies before clinical implementation can be considered.

Topics

Journal Article

Ready to Sharpen Your Edge?

Subscribe to join 11k+ peers who rely on RadAISlice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.